Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Cottu

Showing results (81-90 of 140) with videos related to

Pageof 14
Sort By:
Plos One|October 22, 2013
Genomic instability: a stronger prognostic marker than proliferation for early stage luminal breast carcinomasAnne Vincent-Salomon, Vanessa Benhamo, Eléonore Gravier, et al.
Breast Cancer Research : BCR|May 29, 2020
COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris areaPerrine Vuagnat, Maxime Frelaut, Toulsie Ramtohul, et al.
Plos One|February 28, 2017
Medico-economic impact of MSKCC non-sentinel node prediction nomogram for ER-positive HER2-negative breast cancersHélène Bonsang-Kitzis, Delphine Mouttet-Boizat, Eugénie Guillot, et al.
Breast Cancer Research and Treatment|October 20, 2024
Attrition between lines of therapy and real-world outcomes of patients with HER2-positive metastatic breast cancer in Europe: a cohort study leveraging electronic medical recordsPaul Cottu, Sue Cheeseman, Peter Hall, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2003
Subcutaneous interleukin-2 and interferon alfa administration in patients with metastatic renal cell carcinoma: final results of SCAPP III, a large, multicenter, phase II, nonrandomized study with sequential analysis design--the Subcutaneous Administration Propeukin Program Cooperative GroupJean-Marc Tourani, Christian Pfister, Nicole Tubiana, et al.
Clinical Breast Cancer|July 9, 2023
Long Terms Follow-Up of the Randomized MetaspHER Study Comparing Intravenous Versus Subcutaneous Trastuzumab in Patients' With HER2-Positive Metastatic Breast CancerXavier Pivot, Jean-Philippe Spano, Marc Espie, et al.
Biomaterials|January 9, 2021
In vitro bone metastasis dwelling in a 3D bioengineered nicheWeijing Han, Rania El Botty, Elodie Montaudon, et al.
Breast Cancer Research and Treatment|August 20, 2021
Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded populationMichelino De Laurentiis, Simona Borstnar, Mario Campone, et al.
Breast Cancer Research and Treatment|October 9, 2021
Correction to: Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded populationMichelino De Laurentiis, Simona Borstnar, Mario Campone, et al.
Plos One|March 26, 2013
Long-term prognostic performance of Ki67 rate in early stage, pT1-pT2, pN0, invasive breast carcinomaFabien Reyal, David Hajage, Alexia Savignoni, et al.
Pageof 14

Showing results (81-90 of 140) with videos related to

Sort By:
Pageof 14
Plos One|October 22, 2013
Genomic instability: a stronger prognostic marker than proliferation for early stage luminal breast carcinomasAnne Vincent-Salomon, Vanessa Benhamo, Eléonore Gravier, et al.
Breast Cancer Research : BCR|May 29, 2020
COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris areaPerrine Vuagnat, Maxime Frelaut, Toulsie Ramtohul, et al.
Plos One|February 28, 2017
Medico-economic impact of MSKCC non-sentinel node prediction nomogram for ER-positive HER2-negative breast cancersHélène Bonsang-Kitzis, Delphine Mouttet-Boizat, Eugénie Guillot, et al.
Breast Cancer Research and Treatment|October 20, 2024
Attrition between lines of therapy and real-world outcomes of patients with HER2-positive metastatic breast cancer in Europe: a cohort study leveraging electronic medical recordsPaul Cottu, Sue Cheeseman, Peter Hall, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2003
Subcutaneous interleukin-2 and interferon alfa administration in patients with metastatic renal cell carcinoma: final results of SCAPP III, a large, multicenter, phase II, nonrandomized study with sequential analysis design--the Subcutaneous Administration Propeukin Program Cooperative GroupJean-Marc Tourani, Christian Pfister, Nicole Tubiana, et al.
Clinical Breast Cancer|July 9, 2023
Long Terms Follow-Up of the Randomized MetaspHER Study Comparing Intravenous Versus Subcutaneous Trastuzumab in Patients' With HER2-Positive Metastatic Breast CancerXavier Pivot, Jean-Philippe Spano, Marc Espie, et al.
Biomaterials|January 9, 2021
In vitro bone metastasis dwelling in a 3D bioengineered nicheWeijing Han, Rania El Botty, Elodie Montaudon, et al.
Breast Cancer Research and Treatment|August 20, 2021
Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded populationMichelino De Laurentiis, Simona Borstnar, Mario Campone, et al.
Breast Cancer Research and Treatment|October 9, 2021
Correction to: Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded populationMichelino De Laurentiis, Simona Borstnar, Mario Campone, et al.
Plos One|March 26, 2013
Long-term prognostic performance of Ki67 rate in early stage, pT1-pT2, pN0, invasive breast carcinomaFabien Reyal, David Hajage, Alexia Savignoni, et al.
Pageof 14